PhytoMedical Technologies, Inc. Signs a Letter of Intent (LOI) with a Leading Chinese Research Services Organization Medicilon-MPI Preclinical Research (Shanghai) LLC to Advance Brain Cancer Drug Candidate

Published: Apr 15, 2010

PRINCETON, N.J.--(BUSINESS WIRE)--PhytoMedical Technologies, Inc. (OTCBB: PYTO) (FWB: ET6), a developer of ‘D11B’, an anti-cancer compound shown in early studies to inhibit the growth of difficult-to-treat brain cancer, today announced that the Company has entered into a Letter of Intent (LOI) with Shanghai Medicilon, Inc.

Back to news